Abstract:The process of cancer development and progression is driven by distinct subsets of cancer stem cells (CSCs) that contribute the self-renewal capacity as the major impetus to the metastatic dissemination and main impediments in cancer treatment. Given that CSCs are so scarce in the tumor mass, there are debatable points on the metabolic signatures of CSCs. As opposed to differentiated tumor progenies, CSCs display exquisite patterns of metabolism that, depending on the type of cancer, predominately rely on glycolysis, oxidative metabolism of glutamine, fatty acids, or amino acids for ATP production. Metabolic heterogeneity of CSCs, which attributes to differences in type and microenvironment of tumors, confers CSCs to have the plasticity to cope with the endogenous mitochondrial stress and exogenous microenvironment. In essence, CSCs and normal stem cells are like mirror images of each other in terms of metabolism. To achieve reprogramming, CSCs not only need to upregulate their metabolic engine for self-renewal and defense mechanism, but also expedite the antioxidant defense to sustain the redox homeostasis. In the context of these pathways, this review portrays the connection between the metabolic features of CSCs and cancer stemness. Identification of the metabolic features in conferring resistance to anticancer treatment dictated by CSCs can enhance the opportunity to open up a new therapeutic dimension, which might not only improve the effectiveness of cancer therapies but also annihilate the whole tumor without recurrence. Henceforth, we highlight current findings of potential therapeutic targets for the design of alternative strategies to compromise the growth, drug resistance, and metastasis of CSCs by altering their metabolic phenotypes. Perturbing the versatile skills of CSCs by barricading metabolic signaling might bring about plentiful approaches to discover novel therapeutic targets for clinical application in cancer treatments. Impact statement This minireview highlights the current evidence on the mechanisms of pivotal metabolic pathways that attribute to cancer stem cells (CSCs) with a special focus on developing metabolic strategies of anticancer treatment that can be exploited in preclinical and clinical settings. Specific metabolic inhibitors that can overwhelm the properties of CSCs may impede tumor recurrence and metastasis, and potentially achieve a permanent cure of cancer patients.

Metabolic characterization of sphere‐derived prostate cancer stem cells reveals aberrant urea cycle in stemness maintenance

Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Pro-gression

Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression.

Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer

Lipid metabolism, amino acid metabolism, and prostate cancer: a crucial metabolic journey

Pyrroline-5-carboxylate reductase 1 reprograms proline metabolism to drive breast cancer stemness under psychological stress

Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer*

Phosphodiesterase 5/protein Kinase G Signal Governs Stemness of Prostate Cancer Stem Cells Through Hippo Pathway.

Tumorspheres Derived from Prostate Cancer Cells Possess Chemoresistant and Cancer Stem Cell Properties

Single-cell analysis revealing the metabolic landscape of prostate cancer

Prostate Cancer Stem Cell Biology

Multi-substrate metabolic tracing reveals marked heterogeneity and dependency on fatty acid metabolism in human prostate cancer.

NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer

Identification of Metabolism-Associated Prostate Cancer Subtypes and Construction of a Prognostic Risk Model

Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells

Targeting cancer stem cells from a metabolic perspective

Cancer stem cells: advances in the glucose, lipid and amino acid metabolism

Metabolic Characteristics of Prostate Cancer Cells with High Metastatic Potential Revealed by (S)-Ethyl 1-(3-(4-chlorophenoxy)-2-hydroxypropyl)-3-(4-methoxyphenyl)-1h-pyrazole-5-carboxylate Inhibition

Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer

Distinct Metabolic Signatures of Hormone-Sensitive and Castration-Resistant Prostate Cancer Revealed by a <SUP>1</SUP>H NMR-Based Metabolomics of Biopsy Tissue